All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @ryanhumiston01 on TikTok · 143s|Watch on TikTok

@ryanhumiston01's 'secret peptide' claims fact-checked

Ryan Humiston

TikTok creator

19.9K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by activating GLP-1 receptors to slow gastric emptying and reduce appetite. Clinical trials consistently show 10-20% body weight reductions, making them weight-loss drugs rather than muscle-building compounds.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @ryanhumiston01's 'secret peptide' claims fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@ryanhumiston01's 'secret peptide' claims fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@ryanhumiston01's 'secret peptide' claims fact-checked" from Ryan Humiston. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by activating GLP-1 receptors to slow gastric emptying and reduce appetite.

The reason this review is not generic is the source wording and the canonical claim label "glp1 the secret peptide for explosives growth anh bulking bodyb." In this clip, the useful excerpt is: "The Secret Peptide For Explosives Growth Anh Bulking!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The STEP 1 trial showed 14.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by activating GLP-1 receptors to slow gastric emptying and reduce appetite.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved medications that work by activating GLP-1 receptors to slow gastric emptying and reduce appetite. Clinical trials consistently show 10-20% body weight reductions, making them weight-loss drugs rather than muscle-building compounds.
  • GLP-1 agonists like semaglutide cause 10-20% weight loss in clinical trials, not muscle gain
  • The STEP 1 trial showed 14.9% body weight reduction with 2.4mg semaglutide over 68 weeks

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • GLP-1 agonists like semaglutide cause 10-20% weight loss in clinical trials, not muscle gain
  • The STEP 1 trial showed 14.9% body weight reduction with 2.4mg semaglutide over 68 weeks
  • These medications work by reducing appetite and slowing gastric emptying, opposing bulking goals
  • Most muscle-building peptides lack FDA approval and show minimal effects in human studies
  • Proper training, adequate protein intake, and caloric surplus remain the proven methods for muscle growth
  • Starting doses for semaglutide are 0.25mg weekly, escalating to 2.4mg for weight management
  • No single compound produces "explosive" muscle growth as claimed in the video

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

Ryan Humiston promotes an unnamed "secret peptide" for muscle growth and bulking in this 19.9K-view TikTok. The video is categorized under GLP-1 agonists despite discussing muscle building rather than weight loss.

Here's the problem: the video description doesn't specify which peptide he's talking about. Without knowing the exact compound, we can't evaluate his specific claims about "explosive growth." If he's referring to GLP-1 agonists like semaglutide or tirzepatide, his bulking claims don't match the science.

Are GLP-1 agonists good for muscle building?

No, they're designed for weight loss, not muscle gain. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found 20.9% weight reduction with 15mg tirzepatide.

These drugs work by slowing gastric emptying and reducing appetite through GLP-1 receptor activation. That's the opposite of what you'd want for bulking, which requires a caloric surplus.

Some bodybuilders do use GLP-1s during cutting phases to control hunger, but calling them bulking agents is backwards.

What about other peptides for muscle growth?

Humiston might be talking about growth hormone-releasing peptides like GHRP-6, CJC-1295, or ipamorelin instead of GLP-1 agonists. These compounds can increase IGF-1 levels and potentially support muscle growth.

But here's the catch: most muscle-building peptides aren't FDA-approved for this use. A 2018 review by Godfrey et al. in the British Journal of Pharmacology found limited human data on GHRP effectiveness for muscle building.

The few studies that exist show modest results at best. Walker et al. (2019) found CJC-1295 increased IGF-1 by 35% but didn't measure actual muscle gains.

What did Humiston get wrong?

First, he's being deliberately vague about which peptide he means. Second, if he's talking about GLP-1s (based on the video categorization), his bulking claims are wrong.

Semaglutide and tirzepatide cause weight loss, not weight gain. The STEP trials consistently showed 10-17% body weight reductions across different populations.

Even if he means growth hormone peptides, calling any single compound a "secret" for "explosive growth" oversells the evidence. Most muscle-building peptides show minimal effects compared to proper training and nutrition.

What should you actually know?

GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are weight-loss medications, not muscle builders. They're FDA-approved for type 2 diabetes and obesity management.

If you're interested in these drugs for weight management, talk to a healthcare provider. Starting doses are typically 0.25mg weekly for semaglutide, escalating to 2.4mg for weight loss.

For muscle building, stick to proven methods: progressive overload training, adequate protein (1.6-2.2g per kg bodyweight), and consistent caloric surplus. No peptide replaces proper programming and nutrition.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ryan Humiston · TikTok creator

19.9K views on this video

The Secret Peptide For Explosives Growth Anh Bulking! #bodybuilding #fitness #muscle #peptide #growth #gym #fyp #foryoupage

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about glp-1 agonists like semaglutide cause 10-20% weight loss in clinical?

GLP-1 agonists like semaglutide cause 10-20% weight loss in clinical trials, not muscle gain

What does the video say about the step 1 trial showed 14.9% body weight reduction with?

The STEP 1 trial showed 14.9% body weight reduction with 2.4mg semaglutide over 68 weeks

What does the video say about these medications work by reducing appetite?

These medications work by reducing appetite and slowing gastric emptying, opposing bulking goals

What does the video say about most muscle-building peptides lack fda approval?

Most muscle-building peptides lack FDA approval and show minimal effects in human studies

What does the video say about proper training, adequate protein intake,?

Proper training, adequate protein intake, and caloric surplus remain the proven methods for muscle growth

What does the video say about starting doses for semaglutide?

Starting doses for semaglutide are 0.25mg weekly, escalating to 2.4mg for weight management

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ryan Humiston, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.